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Abstract— DatSCAN Single-photon emission computed 
tomography (SPECT) imaging is a reliable method to assess 
Dopaminergic Transporter in degenerative Parkinsonism. Scan 
without evidence of dopaminergic deficit (SWEDD) are 
subjects clinically diagnosed as Parkinson’s Disease (PD) 
patients although the SPECT imaging does not show any negro-
striatal abnormality. In this paper, five models of machine 
learning were used to carry out binary classification (healthy 
control/PD) using clinical assessment and image-derived 
features applied thereafter on SWEDD group as a potential 
application of motor and non-motors features in understanding 
Parkinson disease characteristic in this group. The nested 
cross-validation was an essential component to select reliable 
models. A high accuracy was achieved for the five models 
(75.4% - 78.4% for motor features and 71% - 82.2% for non-
motor features) in binary classification (HC vs PD). Cross all 
models applied on SWEDD group, 17.6% of patients were 
classified as PD motor disorder lookalikes, 27.4% were 
classified as having a beginning non-motor abnormality of PD 
and 3.9% were classified as having both motor and non-motor 
PD features. According to these facts, we demonstrate the 
suitability and usefulness of ML models to carry out binary 
classification of HC and PD SPECT data. However, the 
interpretability of SWEDD predicted condition must be 
carefully considered. 
Keywords—SPECT; SWEDD;Parkinson’s Disease; Machine 
Learning; SVM, RF; K-NN; MLP; LR 
I.  INTRODUCTION  
he neurodegenerative disease is an umbrella term of a 
wide range of disease linked to the dysfunction of 
neurons and leading to a progressive degeneration and/or death 
of nerve cells [1-3]. The degeneration of nerve cells causes 
movement problems and mental functioning complications 
clinically diagnosed as Alzheimer’s disease (AD) [4, 5], 
Parkinson’s disease (PD) and PD-related disorders [6, 7],  Lewy 
body disease [6, 8, 9] and Huntington’s disease [10-12]. 
Specifically, PD is a neurodegenerative disorder that affects an 
important segment (2-3%) of the elderly population (≥65 years 
of age) [13]. Although, the neurodegeneration mechanisms in 
PD are still unknown, there is convincing evidence of a link 
between neuronal loss in the Substantia Nigra causing 
afterward a striatal dopamine deficiency and PD manifesting. 
Moreover, protein aggregation like alpha-synuclein, the 
presence of Lewy bodies [14] and multiple mechanisms like 
neuroinflammation [15, 16] throughout the central nervous 
system are likely involved in the disease development and its 
progression [17-20].   
PD is characterized by several motor and non-motor features as 
the rigidity, tremors, akinesia, gait and speech disturbance and 
the inability to perform daily functional activities [17]. 
Multiple scales for the quantification of these features have 
been developed such as the Unified Parkinson Disease Rating 
Scale (UPDRS), University of Pennsylvania Smell 
Identification Test (UPSIT), State-Trait Anxiety Inventory 
(STAI), Montreal Cognitive Assessment (MoCA) and Geriatric 
Depression Scales (GDS) [21]. Of these different scales, some 
have gained acceptance in the community-clinician as a clinical 
tool to assess the motor/ non-motor activities and to follow 
patients. Nevertheless, the clinical diagnosis is observable when 
the prevalence of motor and / or functional complications 
manifest clearly.  
Recently, researchers have taken advantage of molecular 
imaging for early PD diagnostic including Positron Emission 
Tomography (PET) [22, 23], MRI [24, 25], Single-photon 
emission computed tomography (SPECT) [26, 27] and the 
novel hybrid modalities (PET-MRI, PET-CT). Specifically, 
SPECT uses a longer half-life radio-marker compared to PET 
and hence it is suitable for the investigation of a large number 
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of patients. SPECT tracers are mostly labeled with either 
iodine-123 or technetium-99m. DaTSCAN (123I ioflupane 
injection) is one of SPECT molecular imaging agent of 
Dopamine Transporter (DAT) imaging which is a biomarker for 
dopamine deficiency [28, 29]. DAT density is commonly 
assessed by calculating the Striatum Binding Ratio (SBR) from 
SPECT data [30].  
Scans without evidence of dopaminergic deficit (SWEDD), 
subjects are clinically labeled as PD patients although the 
molecular imaging (PET and SPECT) does not show any negro-
striatal abnormality. The SWEDD are often subject of 
controversies among authors where a cohort of clinicians and 
researchers suggested that a subset of SWEDD cases  lookalikes 
PD motor disorder, other suggested that some SWEDD cases 
may have a beginning of non-motor abnormality of PD [31]. 
The complexity of the diagnosis of this group of subjects being 
in what the assessment lies on, nigrostriatal imaging or clinic 
scores! Both measurements are exposed to errors and hence 
lying on one or the other leads to an incorrect diagnosis. On the 
other hand, the consideration of image-derived parameters and 
clinical scores in the same sheet constitute a challenge for the 
diagnosis.  
Recently, there has been a great interest in machine learning 
(ML) approaches to assist diagnosis in molecular imaging [32-
37]. Particularly several ML models were applied for prediction 
of PD [38-40]. In this work, we evaluated the performance of a 
set of ML techniques that we used including Support Vector 
Machine (SVM), Neural Networks (NN), Logistic Regression 
(LR), Random Forest (RF) and K-Nearest Neighbor (K-NN) to 
predict SEWDD subjects state as having motor or non-motor 
features. These models were trained and validated on HC and 
PD’s data (n=499, classes number: 2) then used to predict 
SWEDD subjects (n= 51).  
 We used the Parkinson’s Progression Markers Initiative 
(PPMI) to classify SWEDD, PD, and healthy controls (HC) 
according to motor and non-motor symptoms. 
II. MATERIAL AND METHODS 
A. Subjects 
Subjects considered in this study are from the publicly 
available PPMI database (http://www.ppmi-info.org/). Tab.1 
depicts the demographic and the clinical characteristics. 
Participants consisted of healthy controls (n = 157), PD (n = 342) 
and SWEDD (n = 51). 
Table 1: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS 
OF SUBJECTS 
 Healthy 
(n=157) 
PD 
(n=342) 
SWEDD 
(n=51) 
Age 61±11.2 61±9.7 60±10.4 
Sex (M/F) 98/59 226/116 31/20 
UPDRS-III 1.2±2.1 20.6±8.7 14±9.1 
H&N  1.2±1.5 2.2±1.7 1.6±1.3 
UPSIT 34±4.6 22.1±8.2 31.3±5.9 
STAI 94.1±6.9 93±7.8 92±7.3 
MoCA 28.2±1 27.1±2.3 27.2±2.4 
GDS 5.1±1.3 5.2±1.4 5.7±1.6 
UPDRS: Unified Parkinson's disease rating scale; H&N: Hoehn and Yahr score; 
UPSIT: University of Pennsylvania Smell Identification Test; STAI: State-Trait 
Anxiety Inventory; MoCA: Montreal Cognitive Assessment; GDS: Geriatric 
Depression Scales. 
B. Striatum Binding Ratio assessment and clinical scores 
The full description of imaging protocol is available on 
www.ppmi-info.org. Briefly, subjects were injected by similar 
amount of 123I ioflupane (4.61±1.7 mCi) and SPECT data were 
processed by HOSEM iterative reconstruction algorithm using 
HERMES computer software system for all imaging centers to 
ensure consistency of the reconstructions.  
SPECT data were corrected for attenuation then normalized to 
standard Montreal Neurologic Institute (MNI) space so that all 
scans were in the same anatomical alignment (Figure 1). 
 
Figure. 1: One axial slice showing the boundary of the striatum region. A) 
Image of a healthy control, (age 57, injected dose 4.3 mCi) showing the 
integrity of the dopamine in the striatum. B) Image of a PD patient (age 56, 
injected dose 4.8 mCi) showing dopamine deficit at the level of striatum. C) 
Image of a SWEDD, (age 57, injected dose 4.5 mCi) showing the integrity of 
the dopamine in the striatum. 
Next, the transaxial slice with the highest striatal uptake is 
identified on spatial normalized SPECT image volumes. The 
delineation of the striatum region is defined using MRI 
anatomical images and then the adjacent 8 slices (spanning an 
extent of ~ 2 cm) are averaged to generate a single slice image. 
The regions of interest (ROIs) are then placed on the left and 
right caudate, the left and right putamen as a target tissue, and 
a ROI placed on the occipital cortex as a reference tissue. The 
count densities for each region are extracted and used to 
calculate specific binding ratios (SBRs) for each of the striatal 
regions.  The SBR values for each of the 4 striatal regions were 
calculated as (target region/reference region)-1.  
C. Clinical features 
A wide range of symptoms, which characterizes the clinical 
picture of PD, is stratified as motor and non-motor features. The 
commonly used clinical measurement to evaluate the patient 
disease is the UPDRS. The test consists of six diﬀerent parts, 
part I Mentation, Behavior and Mood, part II: Activities of Daily 
Living (ADL), part III: Motor Examination, part IV 
Complications of Therapy, part V: Modiﬁes Hoehn and Yahr 
Staging and part VI: Schwab and England Activities of Daily 
Living Scale: Importantly, the UPDRS III (part III) is used to 
follow the longitudinal course of PD through the motor 
evaluation of disability. From a research standpoint, UPDRS III 
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is an important outcome measure in many clinical trials. It 
consists of 42 items (Speech, Facial expression, Rigidity, 
Finger tapping, Hand movements, Leg agility …. etc) which are 
evaluated by interview and clinical observation and points are 
attributed to each item according to the subject’s condition. The 
single score generated as a sum of individual item’s points 
describing the subject’s motor ability. For instance, 132 points 
(the total points) represents the worst disability and 0 no 
disability [41]. 
Non-motor symptoms are evaluated by common rating 
scales known as, 1) UPSIT which is applied to quantify the 
olfactory function, 2) STAI which is applied to diagnose anxiety 
and to distinguish it from depressive syndromes, 3) MoCA 
which is a screening assessment for detecting cognitive 
impairment and 4) GDS which is useful screening tool to assess 
depression in older adults.  
 
D. Statistics and features selection 
Demographic, injected dose and clinical measures were 
compared using One-way analysis of variance (ANOVA), with 
health condition as fixed factors. Bonferroni correction was 
applied to control for multiple group comparisons. The motor 
scores (UPDRS III) and the image derived features (SBR values 
in the left and right Putamen and the left and right Caudate) were 
put together in the same sheet as a motor features due to the 
strong correlation between these metrics.  Principal component 
analysis (PCA) was then applied on the five dimensions data to 
project the set of image-derived features (SBRs) and motor 
scores on dominant orthogonal axes. PCA were used to expose 
the variation present in the dataset as much as possible. The 
principal components (PCs) are ordered so that the first axes 
retain most of the variation present in original variables. Two 
metrics, the percent contribution of each subject and the squared 
cosine, were used to evaluate the goodness of the projection and 
the ability of the PC to explain the variance within a group of 
subjects. The percent contribution of each participant is defined 
as a ratio of the squared score of observation ݅ on the 
component ݈ ( ௜݂,௟ଶ ) by the eigenvalue associated with the 
component ߣ௟ . The squared cosine metric ܿ݋ݏ௜,௟ଶ  is defined as the 
ratio of squared score factor ௜݂,௟ଶ  by the squared distance of an 
observation ݅ to the origin of the coordinate system [42].  
E. Machine learning approaches 
We carried out binary classification (PD vs healthy control) 
using most common ML models i.e. Support Vector Machines 
(SVM), Random Forests (RFs), Multilayer Perceptron Neural 
Network (MLP), Logistic regression (LR) and K-Nearest 
Neighbor (K-NN). To solve the imbalance problem between HC 
and PD, we used the synthetic minority over-sampling technique 
(SMOTE). The third group (SWEDD) was used for test. Since 
true labels of this group are not available, we conducted a nested 
cross-validation (nested CV) method [43] using the dataset of 
the labeled HC and PD groups. Different V sampling (V1=10 
for the outer loop and V2=5 for the inner loop) were used. The 
data were divided at random into V1 equal parts for the outer 
loop of nested CV; where each of these parts serves in turn as a 
test set and the remaining as a training and validation sets. We 
used V2-fold for the inner loop. A grid-search along with the 
inner cross-validation were conducted to tuning the parameters. 
The best model was selected from the performance of trained 
models in the inner loop. The output performance metrics in 
each iteration of the outer loop were averaged in a single value 
in order to assess the classification accuracy. We also provided 
the confidence interval for the F1 score and the AUC, used to 
evaluate the robustness of these models. 
SVM is a supervised machine learning method used for 
classification, regression, and outlier detection.  SVM has 
several advantages such as 1) very effective in high dimensional 
spaces, 2) robust when the number of dimensions is greater than 
the number of samples, and 3) and it can learn efficiently very 
complex classification functions. SVM classifier consists in 
calculating a maximum margin hyperplane separating two 
classes of the data. For the non-linear separation, the data are 
automatically mapped to a higher dimensional space by means 
of kernel functions, where a separating hyperplane is found. 
New samples are classified according to the side of the 
hyperplane they belong to. In this work, we used the  linear 
basis kernel SVM implementation in libSVM 
(http://www.csie.ntu.edu.tw/~cjlin/libsvm).   
1) RF is a popular ensemble method that can be used to 
build predictive models for classification and regression 
problems.  RF creates an entire forest of random uncorrelated 
decision trees to arrive to the best classification rate possible. 
The idea underlying RF classifier is that it applies a bootstrap 
technique to tree learners by selecting a random sample with 
replacement of the training set and fits trees to these samples. 
This procedure leads to better model performance because it 
decreases the variance of the model, and overcome the 
overfitting problem. The predictions of unseen samples can be 
made by averaging the predictions from all the individual 
regression or classification trees. In this work, we used the ten-
fold corss-validation to validate the model and optimized the 
number of trees over (100,200,500, 1000). We also performed 
an optimization over tree max depth using values between 0 and 
10. 
 
2) MLP is a popular feed-forward neural network algorithm 
for binary classification. MLP consists in mapping an input X 
= (x1, x2, …xn)T ,usually a real-valued vector, to a binary output 
and it is composed of multiple layers of nodes. Each layer is 
being fully connected with to the next layer. Except for the input 
nodes, each hidden unit is determined by forming a weighted 
sum of the unit values in the preceding layer such that the input 
of the unit is given by: 
 ݂(ݔ) = ෌ w୧x୧ + w଴ = ܅୘܆
ୢ
୧ୀଵ  
where W = (w1, w2, …, wd)T is a vector of real-valued weights, 
WTX is the dot product and w0 is the bias. Afterword, each node 
passes this result through a sigmoidal function. 
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For binary classification, f (.) passes through a sigmoid function 
g(.) to obtain output value between 0 and 1.  
The back-propagation algorithm, which is a supervised learning 
technique, is used for training the model. The number of hidden 
layers in the MLP have a significant impact on the classification 
performance. MLP was widely used in different studies related 
to Parkinson disease detection.  .  
3) LR is a regression model where the dependent variable 
is dichotomous (binary). LR is a widely used model, 
specifically in medical domain . LR is used to describe data and 
to explain the relationship between one dependent variable and 
one or more independent variables. 
 
4) K-NN is an instance-based learning algorithm used for 
classification and regression, where the function is only 
approximated locally. K-NN employs distance measure such as 
Euclidean distance to calculate the distance between samples. 
Another important concept in K-NN method, is the parameter 
k, which decides how many neighbors will be chosen for known 
algorithm. The appropriate choice of k has significant impact 
on the performance of the K-NN algorithm. Usually, k is chosen 
to strike a balance between overfitting and underfitting.  
 
III. RESULTS 
A. Subjects clinical measurements comparison 
The factorial ANOVA showed no significant differences in 
age (F(3, 547) = 1.71, p = 0.1), as well as in the 123I ioflupane 
injected dose (F(3, 547) = 0.62, p =0.6). Fisher’s exact tests showed 
no significant differences in the composition of gender (p=0.62). 
Fig2 shows the boxplot of image derived SBR values and the 
clinical scores. The t-test between UPDS III scores in PD and 
HC, between MoCA values in PD and HC and between UPSIT 
values in PD and HC were significant (p<0. 0001, p<0.0001 and 
p<0.0001 respectively). However, the t-test between STAI 
values in PD and HC and between GDS values in PD and HC 
were found not significant (p=0.2 and p=0.4 respectively). 
Figure 2. A) Boxplot of SRB values showing significant differences between 
HC and PD. B) Boxplot of UPDRS III score. C) Boxplot of STAI showing no 
significant difference between HC and PD. D) Boxplot of STAI score showing 
a significant difference between HC and PD. E) Boxplot of MoCA showing a 
significant difference between HC and PD groups. F) Boxplot of GDS showing 
no significant difference between HC and PD groups. 
B. Model validation 
B.1 Motor features  
We retained the two most significant axes to explain data 
from motor features (Dimension = 5). The variance explained by 
the first and the second principal components was equal to 
93.5% of the total variance (Fig 3.A) with PC1 axis accounting 
for 81.8% and PC2 accounting for 11.7% (Figure 3.A). Figure 
3.B shows the correlation of the four variables with the two axes. 
This suggests that if SRB values decrease, then the UPDRS III 
tend to increase. This component can be viewed as a measure of 
dopamine deficit in the striatum. Furthermore, we see that the 
second principal component correlates differently with the SRBs 
in the Putamen and the Caudate suggesting that the deficit of 
dopamine in Putamen is more pronounced than in the Caudate 
(Figure 3.B). 
 
Figure 3. Motor features selection. A) Two principal components were retained 
explaining 93.5% of the total variance. B) Data projection on the two principal 
components. The circle shows the correlation of the features with the axes and 
the ellipses show the variance along the first and the second axis. 
Thereafter, PC scores were served as input to our models. 
Figure.4 schematically describes the flowchart of data 
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Figure 4. Flowchart of machine learning models applied on SPECT data. 
Image-derived SBR values in HC group were significantly higher than in PD 
group and the UPDRS III scores were significantly higher in PD than in HC. 
Models were trained and validated on HC and PD data then used to predict 
SWEDD subjects. 
The selected SVM classifier with an RBF kernel achieved an 
accuracy of 78.4% (F1 score); 95% confidence interval (CI) = 
[74.5%, 82.3%] an AUC of 84.7%; 95% CI = [81.7%, 87.7%].  
The selected MLP classifier achieved an accuracy of 78.3%; 
95% CI = [74.2%, 82.4%] and an AUC of 92.2%; 95% CI = 
[90.7%, 93.8%].  
The selected RF classifier an accuracy of 76.8%; 95% CI = 
[74.1%, 79.5%] and an AUC of 85%; 95% CI = [82%, 88%]. 
The selected K-NN classifier achieved an accuracy of 75.4%; 
95% CI = [72.4%, 78.4%] and an AUC of 82.4%; 95% CI = 
[80.2%, 84.6%] and the selected LR classifier achieved an 
accuracy of 76.2%; 95% CI= [73.3%, 79.1%] and an AUC of 
89%; 95% CI = [84.3%, 93.7%]. 
B.2 Non-Motor features  
Only UPSIT and MoCA scores had a significant difference 
between HC and PD and hence retained as a features vector. 
Figure.5 schematically describes the flowchart of non-motor 
features classification. 
 
 
Figure 5. Flowchart of non-motor features classification. STAI and GDS values 
in PD and HC were not significantly different and hence were removed from 
the chart of machine learning features vector. Models were then trained and 
validated on HC and PD data (UPSIT and MoCA scores) used to predict 
SWEDD subjects. 
 
The selected SVM classifier with an RBF kernel achieved an 
accuracy of 72% (F1 score); 95% CI = [69.3%, 74.7%] and an 
AUC of 81.4%.; 95%; CI = [78.8%, 84%]. 
The MLP classifier achieved an accuracy of 71%; 95% CI = 
[69.3%, 72.7%] and an AUC of 85%; 95% CI = [83.3%, 86.7%].  
The selected RF classifier achieved an accuracy of 72%; 95% CI 
= [70.2.3%, 73.8%] and an AUC of 81.4%; 95% CI = [79.8%, 
83%]. The selected K-NN classifier achieved an accuracy of 
82.2%; 95% CI = [80%, 84.4%] and an AUC of 88%; 95% CI = 
[86.6%, 89.4%] and the selected LR classifier achieved an 
accuracy of 75.6%; 95% CI = [73.3%, 77.8%] and an AUC of 
87.2%; 95% CI = [85.3%, 89.1%]. 
C. Predictive model 
The five models were applied on SWEED as a potential 
application of motor and non-motor features in 
understanding Parkinson disease characteristic in this 
group. 
SVM model was applied on the PC1 and PC2 scores and non-
motor features and provided a classification of SWEDD as 
follow: a 57% of SWEDD patients were classified as PD motor 
disorder lookalikes by the SVM_M model whereas 51% were 
classified as having a beginning non-motor abnormality of PD 
by the SVM_NM. Importantly, 27% of SWEDD patients were 
classified as mimicking both PD motor and non-motor disorder 
and abnormality cross the two models. 
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RF model was applied on the two subsets of features (motor 
and non-motor) and provided a classification of SWEDD as 
follow: a 43% of SWEDD patients were classified as PD with 
motor disorder by the RF_M model and 54% were classified as 
having a beginning non-motor abnormality of PD by the 
RF_NM. Cross the two models, 25% of SWEDD patients were 
classified as having both PD features. 
Similarly, K-NN model was applied on the two set of 
features and provided a classification of SWEDD as follow: a 
25% of SWEDD patients were classified as PD motor disorder 
lookalikes by the K-NN_M model and 63% were classified as 
having a beginning non-motor abnormality of PD by the K-
NN_NM model. Cross the two models, 24% of SWEDD 
patients were classified as having both PD features. 
The MLP model provided a classification of SWEDD as 
follow:  a 47% of SWEDD patients were classified as PD motor 
disorder lookalikes by the MPL_M model and 41% were 
classified as having a beginning non-motor abnormality of PD 
by MPL_NM model. Cross the two models, 26% of SWEDD 
patients were classified as having both PD features. 
The LR model provided a classification of as follow: a 47% 
of SWEDD patients were classified as PD motor disorder 
lookalikes by the first LR_M model and 38% were classified as 
having a beginning non-motor abnormality of PD by the second 
model. Cross the two models, 24% of SWEDD patients were 
classified as having both PD features. 
IV. DISCUSSION 
Machine learning algorithms have been increasingly applied in 
the PD symptoms diagnostics. Most investigations in the 
literature are focusing on the binary classiﬁcation problem of 
PD diagnosis, where machine learning algorithms were applied 
on dataset consisting only of clinical recordings from healthy 
and PD subjects or image derived features but, rarely 
combining the two types of features. For example in [38], 
authors used SVM to discriminate PD among patients with 
various forms of Parkinsonism. Features used in their work 
were only extracted from MRI images. Another study used a 
123I-FP-CIT SPECT data to discriminate healthy controls from 
PD [40]. Authors used 123I-FP-CIT concentration in the left and 
the right Putamen and the left and the right Caudate in addition 
to age as features for the SVM model. Although they found a 
good model accuracy to predict PDs and an important effect of 
age when they analyzed patient with established PD diagnoses, 
that work does have a limitation when investigating patients 
with early suspected Parkinsonism. 
Our conclusion about machine learning methods applied to 
investigate PD are mostly regarding the disease progression or 
to study the primary and secondary Parkinsonism.   
One of the uncommon class of Parkinsonism is known as 
SWEDD. The investigation of SWEDD group is more 
challenging and more complex due to confusing characteristic 
of this group i.e. there is absence of an imaging abnormality in 
patients clinically presumed to have Parkinson's disease (PD). 
To our knowledge, there is only one study investigated this 
group using machine learning technique [44]. The authors 
combined image derived metrics with the olfactory function, 
the genetic risk, the family history of Parkinson's disease, the 
age, and the gender in the same sheet as features to classify 
three groups (HC, PD and SWEDD). They used algorithmically 
these feature in a stepwise logistic regression as significant 
contributors to build their classification model. The study rely 
on one and only one algorithm which raises concerns about the 
efficiency of the model to accurately predict the true SWEDD 
class. The model was tested on PD and SWEDD subjects and 
led particularly to the classification of four (4) out of seventeen 
(17) SWEDD subjects (23%) as having Parkinson's disease. 
Despite the high quality of the analysis (large data from five 
databases were used in this study), this study did not bring a 
decisive answer whether SWEDD are PD lookalikes with motor 
symptoms or PD with non-motor symptoms. 
In this study, we have evaluated a set of the most commonly 
used ML models to discriminate groups in binary classification. 
We aimed in this study primarily to predict the SWEDD group 
as a PD with motor symptoms or PD with non-motor symptoms 
or just a control lookalikes. Although the SWEDD group is 
known to be controversy, our results suggest that these models 
might be useful. The employed features included SBR, which 
has been measured from SPECT data. SBR values were 
computed from almost the eight transaxial striatal slices with the 
highest uptake. This likely leads to an uncertainties because of 
the different conditions of acquisition and the different levels of 
noise generated from different instruments. Therefore, the 
option of relying on SBR metric only for SWEDD diagnosis 
remains a major challenge. For this matter, including the 
clinical assessment is mandatory especially that the SWEDD 
patients overlap with PD in a large spectrum of predicted risk 
who might show later evidence of dopamine deficit or have a 
beginning non-motor abnormality.   
Hence, gathering the image derived SRB metric and the clinical 
assessment of motor activity (UPDRS III) in the same sheet are 
imposed. The UPDRS III feature covers the motor evaluation 
of disability and includes ratings for tremor, slowness 
(bradykinesia), stiffness (rigidity), and balance, which with the 
SPECT data append more information about the motor activity. 
However, SBRs in the two sides of Putamen (left and right) are 
quite similar as well as in the two sides of Caudate (left and 
right). Therefore, using all features for the developed ML leads 
to a redundancy of information [42]. The method used to select 
motor features i.e. PCA is strongly efficient in data compression 
where it reduces attribute space from five variables to a smaller 
number of 2 factors.   
The goodness of the PCA model performance was high. The 
percent contribution of each subject was equitable which means 
that there is no outlier causing a power to build the principal axis. 
The squared cosine was nearly equal to one (0.71-0.98) [42].  
 
To solve the unbalanced data in HC (n=157) and PD (n = 342) 
we applied the SMOTE to oversample the HC. It is well known 
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that the accuracy cannot reflect reliable prediction for the 
minority class and hence applying SMOTE increase trust in 
models accuracy.  The PC output fed the nested CV algorithm 
to select the best model according the minimum mean square 
error (MSE). The optimum parameters of the selected models 
are as follow; the soft-margin SVM penalty parameter was 
found to be C= 10 from the inner loop search-grid. The grid 
parameters range from 0.1—100. The optimum parameter 
gamma from the range 10-6—10-1 was found to be 0.1. For the 
MLP, The optimum size of hidden layer was 2 and the number 
of nodes was 3. For the RF the tree number of 500 and a depth 
of 5 were found. For the KNN the k value was found to be =7 
We selected four non-motor features to evaluate the dopamine-
non-responsive symptoms of Parkinson's disease in the 
SWEDD group. Two strategies were used in this study. The 
first strategy was to use the double cross-validation algorithms 
as defined in [43]. The second strategy rely on the prior 
selection of features based on statistical t-test on the two groups. 
The STAI and GDS scores in HC were statistically not 
distinguishable from PD, and hence were removed from the 
input features. The UPSIT and MoCA, however, were 
statistically different (Figure 2.D and 2.E) which have a 
potential impact on the ML model’s performance. The two 
strategies led almost to the same results. We reported in this 
work only the prior selection in the section B2. 
An important point in our work is the separation of the two 
categories of features to perform our ML models. We choose to 
separate motor from non-motor features to avoid that one 
category outperforms in accuracy the second category. 
Moreover, this strategy lies with the two research directions 
adapted to classify the SEWDD group [31]. 
All the ML models provided quite similar high classification 
results for motor features and with less performance for the non-
motor features. 
Importantly, ten (9) SWEDD patients were classified by all the 
models as PD patients with motor disorder (17.6%), whereas 
fourteen (14) SWEDD patients were classified as PD patients 
with non-motor abnormality (27.4%), and tow (2) SWEDD 
patients classified as PD patients having both motor disorder 
and non-motor abnormality (3.9 %).  
Table 2: SWEDD PATIENTS COMMONLY CLASSIFIED BY 
ALL MODELS AS PD PATIENTS WITH MOTOR DISORDER (√) 
and NON-MOTOR ABNORMALITY (√). 
Subject rank Motor features Non-motor features 
1 √  
2 √  
3  √ 
14 √ √ 
17  √ 
18  √ 
20 √  
21  √ 
23  √ 
31  √ 
37 √ √ 
38 √  
39 √  
41  √ 
42  √ 
43  √ 
44  √ 
45  √ 
46 √  
51 √ √ 
Cross models result add another level of confidence to the 
classification results obtained and demonstrate that motor and 
non-motor features employed in this work could be used to 
confirm whether SWEDD patients have PD features or not. An 
interesting finding obtained in our work is that some SWEDD 
patients were classified by all ML models as PD patients having 
motor disorder. However, the same patients were classified as 
healthy with non-motor abnormality as shown in Table 3.These 
findings suggest that relying only on non-motor features is very 
challenging since it is very difficult to detect PD based on non-
motor features, which may lead to a confusion between 
SWEDD patients and healthy. 
Table 3: SWEDD PATIENTS COMMONLY CLASSIFIED BY 
ALL MODELS AS PD PATIENTS WITH MOTOR DISORDER 
AND HEALTHY WITH NON-MOTOR ABNORMALITY. 
Subject rank Motor features Non-motor features 
1 PD HEALTHY 
20 PD HEALTHY 
In addition, despite the simplicity of some ML models such as 
K-NN and LR, these models show very promising classification 
results compared to the three other models. This suggests that 
simple ML models might be a good choice to perform binary 
classification in similar studies. 
Despite the promising results obtained in our work, some 
limitations that should be taken into account in future work. 1) 
the ground-truth of SWEDD group is not available and hence 
we lack a very important component to affirm the predicted 
state of these subjects 2) in our opinion, a follow-up of the 
SWEDD group is imposed to validate our model. 
V. CONCLUSION 
We propose the current study to demonstrate the feasibility of 
evaluating machine learning algorithms to classify PD subjects 
from HC. The nested cross-validation used in this work was an 
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essential component to select reliable models. The SVM and 
MLP models slightly outperform the other models using motor 
features and so was the K-NN using non-motor features. The 
retained models were applied on SWEDD subjects to predict 
their conditions as a PD patient with motor disorder or as a PD 
patient with non-motor abnormality. The fact that the ground-
truth of this group is unavailable makes the evaluation the 
performance of these models on this group awkward. However, 
we suggest that a merit of investigation by using our models 
might be suitable for a follow-up.  
ACKNOWLEDGMENT  
Authors thank the Parkinson’s Progression Markers Initiative 
(PPMI) and all their funding partners including; The Michael J. 
Fox Foundation for Parkinson's Research, AbbVie, Avid 
radiopharmaceuticals, GE Healthcare and all the other. 
  
REFERENCES 
 
1 Kovacs, G.G.: ‘Concepts and classification of 
neurodegenerative diseases’, Handbook of clinical neurology, 
2017, 145, pp. 301-307 
2 Molteni, M., and Rossetti, C.: ‘Neurodegenerative 
diseases: The immunological perspective’, Journal of 
neuroimmunology, 2017, 313, pp. 109-115 
3 Griesbach, G.S., Masel, B.E., Helvie, R.E., and Ashley, 
M.J.: ‘The Impact of Traumatic Brain Injury on Later Life: 
Effects on Normal Aging and Neurodegenerative Diseases’, 
Journal of neurotrauma, 2017 
4 El Kadmiri, N., Said, N., Slassi, I., El Moutawakil, B., 
and Nadifi, S.: ‘Biomarkers for Alzheimer Disease: Classical 
and Novel Candidates' Review’, Neuroscience, 2017 
5 Pohanka, M.: ‘Alzheimer s disease and oxidative stress: 
a review’, Current medicinal chemistry, 2014, 21, (3), pp. 356-
364 
6 Yau, Y., Zeighami, Y., Baker, T.E., Larcher, K., Vainik, 
U., Dadar, M., Fonov, V.S., Hagmann, P., Griffa, A., Misic, B., 
Collins, D.L., and Dagher, A.: ‘Network connectivity 
determines cortical thinning in early Parkinson's disease 
progression’, Nature communications, 2018, 9, (1), pp. 12 
7 Apfeld, J., and Fontana, W.: ‘Age-Dependence and 
Aging-Dependence: Neuronal Loss and Lifespan in a C. 
elegans Model of Parkinson's Disease’, Biology, 2017, 7, (1) 
8 Londos, E.: ‘Practical Treatment of Lewy Body Disease 
in the Clinic: Patient and Physician Perspectives’, Neurology 
and therapy, 2017 
9 Luzny, J., and Ivanova, K.: ‘DatSCAN In Differential 
Diagnostics of Lewy Body Disease’, Archives of Iranian 
medicine, 2016, 19, (6), pp. 449-452 
10 Whiting, W.L., Velasco, R., and Stewart, J.T.: 
‘Treatment of Behavioral Disinhibition in Huntington's Disease 
With Valproic Acid’, Journal of clinical psychopharmacology, 
2018, 38, (1), pp. 96-98 
11 Espinoza, F.A., Turner, J.A., Vergara, V.M., Miller, 
R.L., Mennigen, E., Liu, J., Misiura, M.B., Ciarochi, J., 
Johnson, H.J., Long, J.D., Bockholt, H.J., Magnota, V.A., 
Paulsen, J.S., and Calhoun, V.D.: ‘Whole-brain connectivity in 
a large study of Huntington's disease gene mutation carriers and 
healthy controls’, Brain connectivity, 2018 
12 Hachigian, L.J., Carmona, V., Fenster, R.J., Kulicke, R., 
Heilbut, A., Sittler, A., Pereira de Almeida, L., Mesirov, J.P., 
Gao, F., Kolaczyk, E.D., and Heiman, M.: ‘Control of 
Huntington's Disease-Associated Phenotypes by the Striatum-
Enriched Transcription Factor Foxp2’, Cell reports, 2017, 21, 
(10), pp. 2688-2695 
13 Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., 
Brundin, P., Volkmann, J., Schrag, A.E., and Lang, A.E.: 
‘Parkinson disease’, Nature reviews. Disease primers, 2017, 3, 
pp. 17013 
14 Hughes, A.J., Daniel, S.E., Kilford, L., and Lees, A.J.: 
‘Accuracy of clinical diagnosis of idiopathic Parkinson's 
disease: a clinico-pathological study of 100 cases’, Journal of 
neurology, neurosurgery, and psychiatry, 1992, 55, (3), pp. 181-
184 
15 Tiwari, P.C., and Pal, R.: ‘The potential role of 
neuroinflammation and transcription factors in Parkinson 
disease’, Dialogues in clinical neuroscience, 2017, 19, (1), pp. 
71-80 
16 Mehta, S.H., and Tanner, C.M.: ‘Role of 
Neuroinflammation in Parkinson Disease: The Enigma 
Continues’, Mayo Clinic proceedings, 2016, 91, (10), pp. 1328-
1330 
17 Poewe, W., and Mahlknecht, P.: ‘The clinical 
progression of Parkinson's disease’, Parkinsonism & related 
disorders, 2009, 15 Suppl 4, pp. S28-32 
18 Brooks, D.J.: ‘Assessment of Parkinson's disease with 
imaging’, Parkinsonism & related disorders, 2007, 13 Suppl 3, 
pp. S268-275 
19 Tolosa, E., Wenning, G., and Poewe, W.: ‘The diagnosis 
of Parkinson's disease’, The Lancet. Neurology, 2006, 5, (1), 
pp. 75-86 
20 Poewe, W.: ‘The natural history of Parkinson's disease’, 
Journal of neurology, 2006, 253 Suppl 7, pp. VII2-6 
21 Ramaker, C., Marinus, J., Stiggelbout, A.M., and Van 
Hilten, B.J.: ‘Systematic evaluation of rating scales for 
impairment and disability in Parkinson's disease’, Movement 
disorders : official journal of the Movement Disorder Society, 
2002, 17, (5), pp. 867-876 
22 Wood, H.: ‘Parkinson disease: 18F-DTBZ PET tracks 
dopaminergic degeneration in patients with Parkinson disease’, 
Nature reviews. Neurology, 2014, 10, (6), pp. 305 
23 Peng, S., Doudet, D.J., Dhawan, V., and Ma, Y.: 
‘Dopamine: PET Imaging and Parkinson Disease’, PET clinics, 
2013, 8, (4), pp. 469-485 
24 Bajaj, S., Krismer, F., Palma, J.A., Wenning, G.K., 
Kaufmann, H., Poewe, W., and Seppi, K.: ‘Diffusion-weighted 
MRI distinguishes Parkinson disease from the parkinsonian 
variant of multiple system atrophy: A systematic review and 
meta-analysis’, PloS one, 2017, 12, (12), pp. e0189897 
25 Ziegler, D.A., and Corkin, S.: ‘New MRI Biomarkers 
Advance the Characterization of Parkinson Disease’, European 
neurological review, 2013, 8, (2), pp. 85-89 
9 
 
26 Suwijn, S.R., de Bruin, K., de Bie, R.M., and Booij, J.: 
‘The role of SPECT imaging of the dopaminergic system in 
translational research on Parkinson's disease’, Parkinsonism & 
related disorders, 2014, 20 Suppl 1, pp. S184-186 
27 Booij, J., and Knol, R.J.: ‘SPECT imaging of the 
dopaminergic system in (premotor) Parkinson's disease’, 
Parkinsonism & related disorders, 2007, 13 Suppl 3, pp. S425-
428 
28 Tagare, H.D., DeLorenzo, C., Chelikani, S., Saperstein, 
L., and Fulbright, R.K.: ‘Voxel-based logistic analysis of PPMI 
control and Parkinson's disease DaTscans’, Neuroimage, 2017, 
152, pp. 299-311 
29 Graebner, A.K., Tarsy, D., Shih, L.C., Vanderhorst, V., 
Kulkarni, O., Kaplan, S., and Simon, D.K.: ‘Clinical Impact of 
123I-Ioflupane SPECT (DaTscan) in a Movement Disorder 
Center’, Neurodegener Dis, 2017, 17, (1), pp. 38-43 
30 Antonini, A., Benti, R., De Notaris, R., Tesei, S., 
Zecchinelli, A., Sacilotto, G., Meucci, N., Canesi, M., Mariani, 
C., Pezzoli, G., and Gerundini, P.: ‘123I-Ioflupane/SPECT 
binding to striatal dopamine transporter (DAT) uptake in 
patients with Parkinson's disease, multiple system atrophy, and 
progressive supranuclear palsy’, Neurological sciences : 
official journal of the Italian Neurological Society and of the 
Italian Society of Clinical Neurophysiology, 2003, 24, (3), pp. 
149-150 
31 Erro, R., Schneider, S.A., Stamelou, M., Quinn, N.P., 
and Bhatia, K.P.: ‘What do patients with scans without 
evidence of dopaminergic deficit (SWEDD) have? New 
evidence and continuing controversies’, Journal of neurology, 
neurosurgery, and psychiatry, 2016, 87, (3), pp. 319-323 
32 Erickson, B.J.: ‘Machine Learning: Discovering the 
Future of Medical Imaging’, Journal of digital imaging, 2017, 
30, (4), pp. 391 
33 Mirzaei, G., Adeli, A., and Adeli, H.: ‘Imaging and 
machine learning techniques for diagnosis of Alzheimer's 
disease’, Reviews in the neurosciences, 2016, 27, (8), pp. 857-
870 
34 Monteiro, E., Costa, C., and Oliveira, J.L.: ‘A machine 
learning methodology for medical imaging anonymization’, 
Conference proceedings : ... Annual International Conference 
of the IEEE Engineering in Medicine and Biology Society. 
IEEE Engineering in Medicine and Biology Society. Annual 
Conference, 2015, 2015, pp. 1381-1384 
35 Shen, D., Wu, G., Zhang, D., Suzuki, K., Wang, F., and 
Yan, P.: ‘Machine learning in medical imaging’, Computerized 
medical imaging and graphics : the official journal of the 
Computerized Medical Imaging Society, 2015, 41, pp. 1-2 
36 Shen, D., Zhang, D., Young, A., and Parvin, B.: 
‘Machine Learning and Data Mining in Medical Imaging’, 
IEEE journal of biomedical and health informatics, 2015, 19, 
(5), pp. 1587-1588 
37 Xia, Y., Ji, Z., Krylov, A., Chang, H., and Cai, W.: 
‘Machine Learning in Multimodal Medical Imaging’, BioMed 
research international, 2017, 2017, pp. 1278329 
38 Haller, S., Badoud, S., Nguyen, D., Barnaure, I., 
Montandon, M.L., Lovblad, K.O., and Burkhard, P.R.: 
‘Differentiation between Parkinson disease and other forms of 
Parkinsonism using support vector machine analysis of 
susceptibility-weighted imaging (SWI): initial results’, 
European radiology, 2013, 23, (1), pp. 12-19 
39 Muniz, A.M., Liu, H., Lyons, K.E., Pahwa, R., Liu, W., 
Nobre, F.F., and Nadal, J.: ‘Comparison among probabilistic 
neural network, support vector machine and logistic regression 
for evaluating the effect of subthalamic stimulation in 
Parkinson disease on ground reaction force during gait’, Journal 
of biomechanics, 2010, 43, (4), pp. 720-726 
40 Palumbo, B., Fravolini, M.L., Buresta, T., Pompili, F., 
Forini, N., Nigro, P., Calabresi, P., and Tambasco, N.: 
‘Diagnostic accuracy of Parkinson disease by support vector 
machine (SVM) analysis of 123I-FP-CIT brain SPECT data: 
implications of putaminal findings and age’, Medicine, 2014, 
93, (27), pp. e228 
41 Martinez-Martin, P., Rodriguez-Blazquez, C., Mario, 
A., Arakaki, T., Arillo, V.C., Chana, P., Fernandez, W., 
Garretto, N., Martinez-Castrillo, J.C., Rodriguez-Violante, M., 
Serrano-Duenas, M., Ballesteros, D., Rojo-Abuin, J.M., 
Chaudhuri, K.R., and Merello, M.: ‘Parkinson's disease severity 
levels and MDS-Unified Parkinson's Disease Rating Scale’, 
Parkinsonism & related disorders, 2015, 21, (1), pp. 50-54 
42 Abdi, H.: ‘Principal component analysis’, Wiley 
Interdisciplinary Reviews: Computational Statistics, 2010, 2, 
(4), pp. 26 
43 Krstajic, D., Buturovic, L.J., Leahy, D.E., and Thomas, 
S.: ‘Cross-validation pitfalls when selecting and assessing 
regression and classification models’, Journal of 
cheminformatics, 2014, 6, (1), pp. 10 
44 Nalls, M.A., McLean, C.Y., Rick, J., Eberly, S., Hutten, 
S.J., Gwinn, K., Sutherland, M., Martinez, M., Heutink, P., 
Williams, N.M., Hardy, J., Gasser, T., Brice, A., Price, T.R., 
Nicolas, A., Keller, M.F., Molony, C., Gibbs, J.R., Chen-
Plotkin, A., Suh, E., Letson, C., Fiandaca, M.S., Mapstone, M., 
Federoff, H.J., Noyce, A.J., Morris, H., Van Deerlin, V.M., 
Weintraub, D., Zabetian, C., Hernandez, D.G., Lesage, S., 
Mullins, M., Conley, E.D., Northover, C.A., Frasier, M., 
Marek, K., Day-Williams, A.G., Stone, D.J., Ioannidis, J.P., 
Singleton, A.B., Parkinson's Disease Biomarkers, P., and 
Parkinson's Progression Marker Initiative, i.: ‘Diagnosis of 
Parkinson's disease on the basis of clinical and genetic 
classification: a population-based modelling study’, The 
Lancet. Neurology, 2015, 14, (10), pp. 1002-1009 
 
 
 
 
 
 
 
 
 
 
 
 
